BIOTON S.A. (BIO.WA)
PLN 3.77
(0.53%)
PLN 3.77
(0.53%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 15.29 Million PLN | -28.05% |
| 2022 | 21.25 Million PLN | 90.71% |
| 2021 | 11.14 Million PLN | -77.05% |
| 2020 | 48.58 Million PLN | 404.79% |
| 2019 | -15.93 Million PLN | 69.59% |
| 2018 | -52.41 Million PLN | -390.7% |
| 2017 | 18.03 Million PLN | 229.77% |
| 2016 | -13.89 Million PLN | 97.24% |
| 2015 | -502.85 Million PLN | -2374.74% |
| 2014 | 22.1 Million PLN | 103.11% |
| 2013 | 10.88 Million PLN | -83.74% |
| 2012 | 66.94 Million PLN | 231.11% |
| 2011 | -51.05 Million PLN | -166.03% |
| 2010 | 77.33 Million PLN | 113.62% |
| 2009 | -567.84 Million PLN | -694.33% |
| 2008 | -71.48 Million PLN | -171.32% |
| 2007 | 100.22 Million PLN | 33.9% |
| 2006 | 74.85 Million PLN | 79.44% |
| 2005 | 41.71 Million PLN | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -2.26 Million PLN | 75.67% |
| 2024 Q1 | -5.36 Million PLN | -150.25% |
| 2023 Q3 | -2.01 Million PLN | -150.05% |
| 2023 Q2 | 4.01 Million PLN | 54.3% |
| 2023 Q1 | 2.6 Million PLN | 5.64% |
| 2023 FY | 15.29 Million PLN | -28.05% |
| 2023 Q4 | 10.68 Million PLN | 631.23% |
| 2022 Q2 | 1.8 Million PLN | 230.22% |
| 2022 Q3 | 3.86 Million PLN | 114.09% |
| 2022 Q4 | 2.46 Million PLN | -36.14% |
| 2022 FY | 21.25 Million PLN | 90.71% |
| 2022 Q1 | 546 Thousand PLN | -81.83% |
| 2021 FY | 11.14 Million PLN | -77.05% |
| 2021 Q1 | 187 Thousand PLN | -99.23% |
| 2021 Q4 | 3 Million PLN | -65.02% |
| 2021 Q2 | 2.55 Million PLN | 1268.45% |
| 2021 Q3 | 8.59 Million PLN | 235.72% |
| 2020 Q4 | 24.37 Million PLN | 518.89% |
| 2020 FY | 48.58 Million PLN | 404.79% |
| 2020 Q1 | 13.89 Million PLN | 133.25% |
| 2020 Q2 | 7.1 Million PLN | -48.88% |
| 2020 Q3 | 3.93 Million PLN | -44.53% |
| 2019 Q1 | -22.5 Million PLN | 57.84% |
| 2019 Q2 | -97.52 Million PLN | -333.4% |
| 2019 Q3 | -1.83 Million PLN | 98.12% |
| 2019 Q4 | -41.78 Million PLN | -2175.65% |
| 2019 FY | -15.93 Million PLN | 69.59% |
| 2018 Q3 | -3.3 Million PLN | -85.43% |
| 2018 Q1 | 6.05 Million PLN | -50.94% |
| 2018 FY | -52.41 Million PLN | -390.7% |
| 2018 Q2 | -1.78 Million PLN | -129.45% |
| 2018 Q4 | -53.37 Million PLN | -1513.63% |
| 2017 Q4 | 12.34 Million PLN | 481.86% |
| 2017 FY | 18.03 Million PLN | 229.77% |
| 2017 Q3 | 2.12 Million PLN | -62.29% |
| 2017 Q2 | 5.62 Million PLN | 372.36% |
| 2017 Q1 | -2.06 Million PLN | 90.61% |
| 2016 Q4 | -21.99 Million PLN | -2362.86% |
| 2016 FY | -13.89 Million PLN | 97.24% |
| 2016 Q1 | 5.37 Million PLN | 101.02% |
| 2016 Q2 | 1.75 Million PLN | -67.29% |
| 2016 Q3 | 972 Thousand PLN | -44.68% |
| 2015 FY | -502.85 Million PLN | -2374.74% |
| 2015 Q4 | -525.93 Million PLN | -3129.9% |
| 2015 Q3 | 17.35 Million PLN | 308.23% |
| 2015 Q2 | 4.25 Million PLN | 190.24% |
| 2015 Q1 | 1.46 Million PLN | -81.89% |
| 2014 FY | 22.1 Million PLN | 103.11% |
| 2014 Q3 | 5.3 Million PLN | 29.06% |
| 2014 Q2 | 4.1 Million PLN | 252.7% |
| 2014 Q4 | 8.09 Million PLN | 52.56% |
| 2014 Q1 | 1.16 Million PLN | -38.03% |
| 2013 FY | 10.88 Million PLN | -83.74% |
| 2013 Q4 | 1.88 Million PLN | -49.87% |
| 2013 Q2 | 65 Thousand PLN | -98.75% |
| 2013 Q1 | 5.18 Million PLN | 177.78% |
| 2013 Q3 | 3.75 Million PLN | 5669.23% |
| 2012 Q2 | -16.31 Million PLN | -120.51% |
| 2012 Q1 | 79.57 Million PLN | 1027.21% |
| 2012 FY | 66.94 Million PLN | 231.11% |
| 2012 Q3 | 1.82 Million PLN | 111.17% |
| 2012 Q4 | 1.86 Million PLN | 2.47% |
| 2011 Q3 | -9.5 Million PLN | 41.42% |
| 2011 FY | -51.05 Million PLN | -166.03% |
| 2011 Q1 | -16.74 Million PLN | -116.02% |
| 2011 Q2 | -16.22 Million PLN | 3.09% |
| 2011 Q4 | -8.58 Million PLN | 9.71% |
| 2010 Q1 | -12.81 Million PLN | 97.51% |
| 2010 Q3 | -10.01 Million PLN | -129.88% |
| 2010 FY | 77.33 Million PLN | 113.62% |
| 2010 Q4 | 104.51 Million PLN | 1143.3% |
| 2010 Q2 | -4.35 Million PLN | 65.99% |
| 2009 Q3 | -7.21 Million PLN | 81.26% |
| 2009 Q4 | -514.84 Million PLN | -7036.72% |
| 2009 Q2 | -38.5 Million PLN | -428.56% |
| 2009 Q1 | -7.28 Million PLN | 0.0% |
| 2009 FY | -567.84 Million PLN | -694.33% |
| 2008 FY | -71.48 Million PLN | -171.32% |
| 2007 FY | 100.22 Million PLN | 33.9% |
| 2006 FY | 74.85 Million PLN | 79.44% |
| 2005 FY | 41.71 Million PLN | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Bioceltix S.A. | -15.81 Million PLN | 196.684% |
| Captor Therapeutics Spolka Akcyjna | -73.01 Million PLN | 120.947% |
| Mabion S.A. | 55.06 Million PLN | 72.222% |
| Molecure S.A. | -22.1 Million PLN | 169.197% |
| NanoGroup S.A. | -7.9 Million PLN | 293.561% |
| Pharmena S.A. | 34.87 Million PLN | 56.138% |
| Poltreg S.A. | -16.86 Million PLN | 190.707% |
| Pure Biologics Spólka Akcyjna | -31.71 Million PLN | 148.222% |
| Ryvu Therapeutics S.A. | -100.94 Million PLN | 115.151% |
| Synthaverse S.A. | 8.64 Million PLN | -76.882% |
| Urteste S.A. | -6.44 Million PLN | 337.242% |